We only have this paper's title and publication details.
Read it at the sourcePhase 2 subgroup analysis reports efficacy and safety outcomes of idelalisib in relapsed, rituximab- and alkylating-refractory follicular lymphoma, indicating a targeted treatment option.
International audience
No takes yet. Share an insight, caveat, or question.
Salles et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: